Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials

Evaluation of the Utility of an Environmental Exposure Chamber (EEC) for Assessing Efficacy of Specific Immunotherapy (SIT) in Pivotal Clinical Trials

The study will explore how allergy symptoms experienced during the grass pollen season compare to symptoms experienced in the Environmental Exposure Chamber (EEC).

There are 2 treatments in this study. Both treatments are injected under the skin. Allergovit® Grasses works by helping the body's immune system get used to grass-pollen before the grass pollen season begins which may lead to decreased sensitivity and reduced allergy symptoms during the grass season. Placebo treatment does not contain grass pollen mixture, and is not expected to reduce allergic symptoms overtime.

Study Overview

• Status: Terminated
• Conditions: Healthy Volunteers; Allergic Rhinoconjunctivitis
• Intervention / Treatment: Drug: Placebo; Biological: Allergovit 6-grasses

Detailed Description

This is a Phase II trial, with a one year observational/baseline phase followed by a one year double-blind placebo-controlled, randomized, treatment phase. Approx. 137 grass pollen-allergic subjects and 20 non-allergic subjects will be enrolled in the baseline phase of the study. The primary objective of the trial is to investigate the relationship between allergy symptoms experienced by subjects (allergic and non-allergic) upon exposure to grass pollen-allergen in the EEC and the allergy symptoms experienced by subjects during the grass pollen season.

• Study Type: Interventional
• Enrollment (Actual): 158
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Mississauga, Ontario, Canada, L4W 1A4
      • Inflamax Research INC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• IgE-mediated seasonal allergic rhinitis/rhinoconjunctivitis with or without allergic asthma
• positive skin prick test
• specific IgE ≥ 0.70 kU/L to mixture of grass pollen allergens
• symptom score of at least 4 per day during the week following the peak-pollen count in the baseline season

Exclusion Criteria:

• undergone previous specific immunotherapy with grass pollen allergens in any formulation less than 5 years prior to the screening date
• currently undergoing any sort of immunotherapy, or has ever undergone specific immunotherapy with unknown allergen
• allergens which are expected to interfere with the grass pollen season
• uncontrolled or partly controlled asthma
• patients with contraindications for SIT

Study Plan

How is the study designed?

Design Details

• Primary Purpose: BASIC_SCIENCE
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
PLACEBO_COMPARATOR: Placebo; Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.	Drug: Placebo; Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.; Other Names: Comparator
EXPERIMENTAL: Allergovit 6-grasses immunotherapy; Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.	Biological: Allergovit 6-grasses; Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.; Other Names: Specific immunotherapy with an allergoid preparation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total Symptom Score (TSS)	Analysis of the relationship between different methods of measurement of efficacy of SIT. The AUC of the Total Symptom Score (TSS) as primary endpoint assessed in an EEC after preseasonal treatment	1 year
Rhinoconjunctivitis Symptom and Medication Score (RC-SMS)	The AUC of the Rhinoconjunctivitis Symptom and Medication Score (RC-SMS) assessed as primary endpoint during the natural grass pollen season (field-based)	Grass pollen season from March until July (approx. 11 weeks avarage)
Medication-adjusted Rhinoconjunctivitis Symptom Score (ma-RC-SS)	The AUC of the Medication-adjusted Rhinoconjunctivitis Symptom Score (ma-RC-SS) assessed as primary endpoint during the natural grass pollen season (field-based)	Grass pollen season from March until July (approx. 11 weeks avarage)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Symptoms (by TSS, RC-SMS, ma-RC-SS) in non-allergic subjects	Evaluation of the relationship of symptoms experienced in EEC and natural grass pollen season. Assessment of symptom specificity provoked by EEC in non-allergic subjects.	1 year

Collaborators and Investigators

• Sponsor: Allergopharma GmbH & Co. KG
• Collaborators: Inflamax Research Incorporated
• Investigators: Principal Investigator: Piyush Patel, Dr.

Study record dates

Study Major Dates

• Study Start: January 1, 2014
• Primary Completion (ACTUAL): November 1, 2014
• Study Completion (ACTUAL): December 1, 2014

Study Registration Dates

• First Submitted: November 12, 2014
• First Submitted That Met QC Criteria: November 19, 2014
• First Posted (ESTIMATE): November 21, 2014

Study Record Updates

• Last Update Posted (ACTUAL): January 17, 2018
• Last Update Submitted That Met QC Criteria: January 16, 2018
• Last Verified: January 1, 2018

More Information

Terms related to this study

• Keywords: Environmental Exposure Chamber; Specific Immunotherapy; SCIT; SIT
• Other Study ID Numbers: AL1304AV; AL13BP01 (OTHER: Inflamax Research INC.)